Was  ||| S:0 E:4 ||| VBD
Cipriani  ||| S:4 E:13 ||| NNP
right ||| S:13 E:18 ||| NN
?  ||| S:18 E:20 ||| .
Audits  ||| S:20 E:27 ||| NN
to  ||| S:27 E:30 ||| TO
compare  ||| S:30 E:38 ||| VB
discharge  ||| S:38 E:48 ||| JJ
rates  ||| S:48 E:54 ||| NNS
and  ||| S:54 E:58 ||| CC
suicidality  ||| S:58 E:70 ||| NN
between  ||| S:70 E:78 ||| IN
antidepressant  ||| S:78 E:93 ||| NNS
monotherapies  ||| S:93 E:107 ||| VBP
used  ||| S:107 E:112 ||| VBN
in  ||| S:112 E:115 ||| IN
a  ||| S:115 E:117 ||| DT
British  ||| S:117 E:125 ||| JJ
community  ||| S:125 E:135 ||| NN
mental  ||| S:135 E:142 ||| JJ
health  ||| S:142 E:149 ||| NN
team  ||| S:149 E:154 ||| NN
a  ||| S:154 E:156 ||| DT
Metanalysis  ||| S:156 E:168 ||| NNP
by  ||| S:168 E:171 ||| IN
Cipriani  ||| S:171 E:180 ||| NNP
recently  ||| S:180 E:189 ||| RB
showed  ||| S:189 E:196 ||| VBD
that  ||| S:196 E:201 ||| DT
certain  ||| S:201 E:209 ||| JJ
antidepressants  ||| S:209 E:225 ||| NN
were  ||| S:225 E:230 ||| VBD
more  ||| S:230 E:235 ||| RBR
effective  ||| S:235 E:245 ||| JJ
and  ||| S:245 E:249 ||| CC
better  ||| S:249 E:256 ||| JJR
tolerated  ||| S:256 E:266 ||| NN
than  ||| S:266 E:271 ||| IN
others ||| S:271 E:277 ||| NNS
.  ||| S:277 E:279 ||| .
We  ||| S:279 E:282 ||| PRP
wished  ||| S:282 E:289 ||| VBD
to  ||| S:289 E:292 ||| TO
see  ||| S:292 E:296 ||| VB
whether  ||| S:296 E:304 ||| IN
these  ||| S:304 E:310 ||| DT
findings  ||| S:310 E:319 ||| NNS
were  ||| S:319 E:324 ||| VBD
reflected  ||| S:324 E:334 ||| VBN
in  ||| S:334 E:337 ||| IN
the  ||| S:337 E:341 ||| DT
outcomes  ||| S:341 E:350 ||| NN
of  ||| S:350 E:353 ||| IN
depression  ||| S:353 E:364 ||| NN
treatment  ||| S:364 E:374 ||| NN
in  ||| S:374 E:377 ||| IN
our  ||| S:377 E:381 ||| PRP$
Community  ||| S:381 E:391 ||| NNP
Mental  ||| S:391 E:398 ||| NNP
Health  ||| S:398 E:405 ||| NNP
Team  ||| S:405 E:410 ||| NNP
( ||| S:410 E:411 ||| -LRB-
CMHT ||| S:411 E:415 ||| NNP
) ||| S:415 E:416 ||| -RRB-
.  ||| S:416 E:418 ||| .
we  ||| S:418 E:421 ||| PRP
related  ||| S:421 E:429 ||| JJ
medication  ||| S:429 E:440 ||| NN
choice  ||| S:440 E:447 ||| NN
and  ||| S:447 E:451 ||| CC
dosage  ||| S:451 E:458 ||| JJ
range  ||| S:458 E:464 ||| NN
to  ||| S:464 E:467 ||| TO
outcomes  ||| S:467 E:476 ||| VB
of  ||| S:476 E:479 ||| IN
treatment  ||| S:479 E:489 ||| NN
as  ||| S:489 E:492 ||| IN
reflected  ||| S:492 E:502 ||| VBN
by  ||| S:502 E:505 ||| IN
discharge  ||| S:505 E:515 ||| JJ
rates  ||| S:515 E:521 ||| NNS
and  ||| S:521 E:525 ||| CC
suicidality.  ||| S:525 E:538 ||| CD
in  ||| S:538 E:541 ||| IN
this  ||| S:541 E:546 ||| DT
paper  ||| S:546 E:552 ||| NN
we  ||| S:552 E:555 ||| PRP
emphasize  ||| S:555 E:565 ||| VB
the  ||| S:565 E:569 ||| DT
relationship  ||| S:569 E:582 ||| NN
of  ||| S:582 E:585 ||| IN
Dose  ||| S:585 E:590 ||| NNP
Range  ||| S:590 E:596 ||| NNP
to  ||| S:596 E:599 ||| TO
outcome ||| S:599 E:606 ||| NN
.  ||| S:606 E:608 ||| .
Our  ||| S:608 E:612 ||| PRP$
results  ||| S:612 E:620 ||| NNS
are  ||| S:620 E:624 ||| VBP
in  ||| S:624 E:627 ||| IN
accord  ||| S:627 E:634 ||| NN
with  ||| S:634 E:639 ||| IN
those  ||| S:639 E:645 ||| DT
of  ||| S:645 E:648 ||| IN
Cipriani ||| S:648 E:656 ||| NNP
.  ||| S:656 E:658 ||| .
We  ||| S:658 E:661 ||| PRP
note  ||| S:661 E:666 ||| VBP
that  ||| S:666 E:671 ||| IN
Prescription  ||| S:671 E:684 ||| NNP
of  ||| S:684 E:687 ||| IN
' ||| S:687 E:688 ||| ''
the  ||| S:688 E:692 ||| DT
four ||| S:692 E:696 ||| CD
'  ||| S:696 E:698 ||| ''
was  ||| S:698 E:702 ||| VBD
associated  ||| S:702 E:713 ||| VBN
with  ||| S:713 E:718 ||| IN
a  ||| S:718 E:720 ||| DT
greater  ||| S:720 E:728 ||| JJR
percentage  ||| S:728 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
patients  ||| S:742 E:751 ||| NNS
discharged  ||| S:751 E:762 ||| VBN
from  ||| S:762 E:767 ||| IN
the  ||| S:767 E:771 ||| DT
clinic  ||| S:771 E:778 ||| NN
than  ||| S:778 E:783 ||| IN
' ||| S:783 E:784 ||| ''
the  ||| S:784 E:788 ||| DT
others ||| S:788 E:794 ||| NNS
' ||| S:794 E:795 ||| POS
.  ||| S:795 E:797 ||| .
Sertraline  ||| S:797 E:808 ||| NNP
was  ||| S:808 E:812 ||| VBD
the  ||| S:812 E:816 ||| DT
antidepressant  ||| S:816 E:831 ||| JJ
most  ||| S:831 E:836 ||| RBS
likely  ||| S:836 E:843 ||| JJ
to  ||| S:843 E:846 ||| TO
reduce  ||| S:846 E:853 ||| VB
suicidality  ||| S:853 E:865 ||| VBN
in  ||| S:865 E:868 ||| IN
our  ||| S:868 E:872 ||| PRP$
sample ||| S:872 E:878 ||| NN
.  ||| S:878 E:880 ||| .
For  ||| S:880 E:884 ||| IN
patients  ||| S:884 E:893 ||| NNS
with  ||| S:893 E:898 ||| IN
unipolar  ||| S:898 E:907 ||| JJ
depression ||| S:907 E:917 ||| NN
,  ||| S:917 E:919 ||| ,
discharge  ||| S:919 E:929 ||| JJ
rates  ||| S:929 E:935 ||| NNS
were  ||| S:935 E:940 ||| VBD
higher  ||| S:940 E:947 ||| JJR
when  ||| S:947 E:952 ||| WRB
they  ||| S:952 E:957 ||| PRP
were  ||| S:957 E:962 ||| VBD
prescribed  ||| S:962 E:973 ||| VBN
one  ||| S:973 E:977 ||| CD
of  ||| S:977 E:980 ||| IN
the  ||| S:980 E:984 ||| DT
four  ||| S:984 E:989 ||| CD
medications  ||| S:989 E:1001 ||| NNS
indicated  ||| S:1001 E:1011 ||| VBD
by  ||| S:1011 E:1014 ||| IN
Cipriani  ||| S:1014 E:1023 ||| NNP
and  ||| S:1023 E:1027 ||| CC
highest  ||| S:1027 E:1035 ||| JJS
when  ||| S:1035 E:1040 ||| WRB
prescribed  ||| S:1040 E:1051 ||| JJ
escitalopram ||| S:1051 E:1063 ||| NN
.  ||| S:1063 E:1065 ||| .
For  ||| S:1065 E:1069 ||| IN
patients  ||| S:1069 E:1078 ||| NNS
who  ||| S:1078 E:1082 ||| WP
also  ||| S:1082 E:1087 ||| RB
had  ||| S:1087 E:1091 ||| VBD
other  ||| S:1091 E:1097 ||| JJ
indications ||| S:1097 E:1108 ||| NNS
,  ||| S:1108 E:1110 ||| ,
discharge  ||| S:1110 E:1120 ||| JJ
rates  ||| S:1120 E:1126 ||| NNS
were  ||| S:1126 E:1131 ||| VBD
higher  ||| S:1131 E:1138 ||| JJR
for  ||| S:1138 E:1142 ||| IN
the  ||| S:1142 E:1146 ||| DT
group  ||| S:1146 E:1152 ||| NN
other  ||| S:1152 E:1158 ||| JJ
than  ||| S:1158 E:1163 ||| IN
the  ||| S:1163 E:1167 ||| DT
four  ||| S:1167 E:1172 ||| CD
antidepressants  ||| S:1172 E:1188 ||| NNS
identified  ||| S:1188 E:1199 ||| VBN
by  ||| S:1199 E:1202 ||| IN
Cipriani  ||| S:1202 E:1211 ||| NNP
and  ||| S:1211 E:1215 ||| CC
highest  ||| S:1215 E:1223 ||| JJS
for  ||| S:1223 E:1227 ||| IN
fluoxetine ||| S:1227 E:1237 ||| NN
.  ||| S:1237 E:1239 ||| .
Regarding  ||| S:1239 E:1249 ||| VBG
Dose  ||| S:1249 E:1254 ||| NNP
Ranges ||| S:1254 E:1260 ||| NNP
,  ||| S:1260 E:1262 ||| ,
we  ||| S:1262 E:1265 ||| PRP
note  ||| S:1265 E:1270 ||| VBP
that  ||| S:1270 E:1275 ||| IN
wheras  ||| S:1275 E:1282 ||| JJ
many  ||| S:1282 E:1287 ||| JJ
patients  ||| S:1287 E:1296 ||| NNS
had  ||| S:1296 E:1300 ||| VBD
their  ||| S:1300 E:1306 ||| PRP$
dosage  ||| S:1306 E:1313 ||| JJ
titrated  ||| S:1313 E:1322 ||| JJ
upwards  ||| S:1322 E:1330 ||| NN
from  ||| S:1330 E:1335 ||| IN
the  ||| S:1335 E:1339 ||| DT
starting  ||| S:1339 E:1348 ||| VBG
dose ||| S:1348 E:1352 ||| NN
,  ||| S:1352 E:1354 ||| ,
most  ||| S:1354 E:1359 ||| JJS
did  ||| S:1359 E:1363 ||| VBD
not  ||| S:1363 E:1367 ||| RB
have  ||| S:1367 E:1372 ||| VB
the  ||| S:1372 E:1376 ||| DT
dosage  ||| S:1376 E:1383 ||| JJ
titrated  ||| S:1383 E:1392 ||| NN
to  ||| S:1392 E:1395 ||| TO
the  ||| S:1395 E:1399 ||| DT
highest  ||| S:1399 E:1407 ||| JJS
dose  ||| S:1407 E:1412 ||| NN
of  ||| S:1412 E:1415 ||| IN
the  ||| S:1415 E:1419 ||| DT
relevant  ||| S:1419 E:1428 ||| JJ
medication.  ||| S:1428 E:1440 ||| NN
it  ||| S:1440 E:1443 ||| PRP
does  ||| S:1443 E:1448 ||| VBZ
appear  ||| S:1448 E:1455 ||| VB
that  ||| S:1455 E:1460 ||| IN
the  ||| S:1460 E:1464 ||| DT
antidepressants  ||| S:1464 E:1480 ||| NN
identified  ||| S:1480 E:1491 ||| VBN
by  ||| S:1491 E:1494 ||| IN
Cipriani  ||| S:1494 E:1503 ||| NNP
are  ||| S:1503 E:1507 ||| VBP
effective  ||| S:1507 E:1517 ||| JJ
compared  ||| S:1517 E:1526 ||| VBN
with  ||| S:1526 E:1531 ||| IN
other  ||| S:1531 E:1537 ||| JJ
monotherapies ||| S:1537 E:1550 ||| NN
.  ||| S:1550 E:1552 ||| .
Medication  ||| S:1552 E:1563 ||| NN
doses  ||| S:1563 E:1569 ||| NNS
need  ||| S:1569 E:1574 ||| VBP
to  ||| S:1574 E:1577 ||| TO
be  ||| S:1577 E:1580 ||| VB
optimised  ||| S:1580 E:1590 ||| VBN
in  ||| S:1590 E:1593 ||| IN
order  ||| S:1593 E:1599 ||| NN
to  ||| S:1599 E:1602 ||| TO
achieve  ||| S:1602 E:1610 ||| VB
optimal  ||| S:1610 E:1618 ||| JJ
treatment  ||| S:1618 E:1628 ||| NN
in  ||| S:1628 E:1631 ||| IN
Depression ||| S:1631 E:1641 ||| NNP
.  ||| S:1641 E:1643 ||| .
Our  ||| S:1643 E:1647 ||| PRP$
results  ||| S:1647 E:1655 ||| NNS
suggest  ||| S:1655 E:1663 ||| VBP
that  ||| S:1663 E:1668 ||| IN
co-morbid  ||| S:1668 E:1678 ||| JJ
undiagnosed  ||| S:1678 E:1690 ||| JJ
other  ||| S:1690 E:1696 ||| JJ
mental  ||| S:1696 E:1703 ||| JJ
illness  ||| S:1703 E:1711 ||| NN
may  ||| S:1711 E:1715 ||| MD
often  ||| S:1715 E:1721 ||| RB
be  ||| S:1721 E:1724 ||| VB
a  ||| S:1724 E:1726 ||| DT
cause  ||| S:1726 E:1732 ||| NN
of  ||| S:1732 E:1735 ||| IN
' ||| S:1735 E:1736 ||| POS
resistant  ||| S:1736 E:1746 ||| JJ
depression ||| S:1746 E:1756 ||| NN
' ||| S:1756 E:1757 ||| POS
.  ||| S:1757 E:1759 ||| .
We  ||| S:1759 E:1762 ||| PRP
recommend  ||| S:1762 E:1772 ||| VBP
that  ||| S:1772 E:1777 ||| IN
all  ||| S:1777 E:1781 ||| DT
CMHTs  ||| S:1781 E:1787 ||| NN
should  ||| S:1787 E:1794 ||| MD
carry  ||| S:1794 E:1800 ||| VB
out  ||| S:1800 E:1804 ||| RP
audits  ||| S:1804 E:1811 ||| NN
of  ||| S:1811 E:1814 ||| IN
their  ||| S:1814 E:1820 ||| PRP$
prescribing  ||| S:1820 E:1832 ||| JJ
practice  ||| S:1832 E:1841 ||| NN
in  ||| S:1841 E:1844 ||| IN
order  ||| S:1844 E:1850 ||| NN
to  ||| S:1850 E:1853 ||| TO
optimise  ||| S:1853 E:1862 ||| VB
treatment  ||| S:1862 E:1872 ||| NN
outcomes ||| S:1872 E:1880 ||| NNS
.  ||| S:1880 E:1882 ||| .
